Cost analysis of glatiramer acetate versus interferon-β for relapsing-remitting multiple sclerosis in patients with spasticity: the Escala study

被引：0
|
作者：
Rainel Sánchez-de la Rosa
Laura García-Bujalance
José Meca-Lallana
机构：
[1] Medical Department,Neurology Department
[2] TEVA Pharmaceutical,undefined
[3] Market Access & Regulatory Department,undefined
[4] TEVA Pharmaceutical,undefined
[5] Hospital Clínico Universitario Virgen de la Arrixaca,undefined
来源：
Health Economics Review | / 5卷
关键词：
Cost analysis; Glatiramer acetate; Interferon-β; Relapsing-remitting multiple sclerosis; Spasticity;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 50 条
  • [1] Cost analysis of glatiramer acetate versus interferon-β for relapsing-remitting multiple sclerosis in patients with spasticity: the Escala study
    Sanchez-de la Rosa, Rainel
    Garcia-Bujalance, Laura
    Meca-Lallana, Jose
    HEALTH ECONOMICS REVIEW, 2015, 5
  • [2] Spasticity improvement in patients with relapsing-remitting multiple sclerosis switching from interferon-β to glatiramer acetate: The Escala Study
    Meca-Lallana, J. E.
    Balseiro, J. J.
    Lacruz, F.
    Guijarro, C.
    Sanchez, O.
    Cano, A.
    Costa-Frossard, L.
    Hernandez-Clares, R.
    Sanchez-de la Rosa, R.
    JOURNAL OF THE NEUROLOGICAL SCIENCES, 2012, 315 (1-2) : 123 - 128
  • [3] COST ANALYSIS OF THE USE OF GLATIRAMER ACETATE COMPARED TO INTERFERON-A IN PATIENTS WITH RELAPSING-REMITTING MULTIPLE SCLEROSIS AND SPASTICITY IN SPAIN
    Sanchez de la Rosa, R.
    Garcia Bujalance, L.
    Meca Lallana, J.
    VALUE IN HEALTH, 2014, 17 (07) : A394 - A394
  • [4] Comparative efficacy of interferon β versus glatiramer acetate for relapsing-remitting multiple sclerosis
    La Mantia, Loredana
    Di Pietrantonj, Carlo
    Rovaris, Marco
    Rigon, Giulio
    Frau, Serena
    Berardo, Francesco
    Gandini, Anna
    Longobardi, Anna
    Weinstock-Guttman, Bianca
    Vaona, Alberto
    JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY, 2015, 86 (09): : 1016 - 1020
  • [5] COST ANALYSIS OF GLATIRAMER ACETATE VERSUS FINGOLIMOD FOR THE TREATMENT OF PATIENTS WITH RELAPSING-REMITTING MULTIPLE SCLEROSIS IN SPAIN
    Sanchez-de la Rosa, R.
    Sabater, E.
    Casado, M. A.
    VALUE IN HEALTH, 2012, 15 (07) : A551 - A551
  • [6] Cost effectiveness of glatiramer acetate and natalizumab in relapsing-remitting multiple sclerosis
    Stephanie R. Earnshaw
    Jonathan Graham
    MerriKay Oleen-Burkey
    Jane Castelli-Haley
    Kenneth Johnson
    Applied Health Economics and Health Policy, 2009, 7 (2) : 91 - 108
  • [7] Cost Effectiveness of Glatiramer Acetate and Natalizumab in Relapsing-Remitting Multiple Sclerosis
    Earnshaw, Stephanie
    Graham, Jonathan
    Oleen-Burkey, MerriKay
    Castelli-Haley, Jane
    Johnson, Kenneth
    APPLIED HEALTH ECONOMICS AND HEALTH POLICY, 2009, 7 (02) : 91 - 108
  • [8] Fingolimod versus glatiramer acetate in patients with relapsing-remitting multiple sclerosis - ASSESS study results
    Cree, B. A.
    Goldman, M. D.
    Corboy, J. R.
    Singer, B.
    Fox, E.
    Arnold, D. L.
    Ford, C.
    Weinstock-Guttman, B.
    Bar-or, A.
    Mientus, S.
    Sienkiewicz, D.
    Zhang, Y.
    Karan, R.
    Tenenbaum, N.
    EUROPEAN JOURNAL OF NEUROLOGY, 2019, 26 : 163 - 163
  • [9] Spotlight on glatiramer acetate in relapsing-remitting multiple sclerosis
    Simpson, D
    Noble, S
    Perry, C
    BIODRUGS, 2003, 17 (03) : 207 - 210
  • [10] Glatiramer acetate for treatment of relapsing-remitting multiple sclerosis
    Johnson, Kenneth P.
    EXPERT REVIEW OF NEUROTHERAPEUTICS, 2012, 12 (04) : 371 - 384
12345